NCT06335147View on ClinicalTrials.gov

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Metastatic Colon Cancer
Interventions
DRUG

Serplulimab, mFOLFOX6

Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT06335147 - PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer | Biotech Hunter | Biotech Hunter